K Number
K992712
Date Cleared
1999-12-06

(117 days)

Product Code
Regulation Number
864.7925
Panel
HE
Reference & Predicate Devices
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

Sigma Diagnostics ALEXIN™ LS is a device used for primary screening for coagulation Shina Diagnest of evaluation of the effect of therapy on procoagulant disorders, and as able mail.com factor deficiencies of the intrinsic coagulation pathway.

Device Description

Sigma Diagnostics ALEXIN™ LS contains purified rabbit brain and sov phospholipids with an ellagic acid activator for the determination of the activated partial thromboplastin time and related coagulation procedures in citrated plasma. This reagent has increased sensitivity to lupus anticoagulants.

AI/ML Overview

The provided document describes the safety and effectiveness study for the Sigma Diagnostics ALEXIN™ LS device, demonstrating its substantial equivalence to the Dade Actin-FSL device.

Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance:

The primary acceptance criteria for this device appear to be a strong correlation and agreement with a legally marketed predicate device (Dade Actin-FSL). The precision data also represents performance within expected ranges for such assays.

Acceptance Criteria CategorySpecific Criteria (Implied)Reported Device Performance (ALEXIN™ LS vs. Dade Actin-FSL)
Correlation CoefficientHigh correlation (e.g., > 0.90) between ALEXIN™ LS and predicate deviceOptical Mode: 0.97
Mechanical Mode: 0.98
KC 4A Analyzer: 0.95
Regression Equation (Slope/Intercept)Close agreement (slope near 1, intercept near 0)Optical Mode: y = 0.91x + 0.10
Mechanical Mode: y = 0.92x + 0.08
KC 4A Analyzer: y = 0.86x + 0.15
Precision (Within-Run CV%)Low variability (typically

§ 864.7925 Partial thromboplastin time tests.

(a)
Identification. A partial thromboplastin time test is a device used for primary screening for coagulation abnormalities, for evaluation of the effect of therapy on procoagulant disorders, and as an assay for coagulation factor deficiencies of the intrinsic coagulation pathway.(b)
Classification. Class II (performance standards).